Lansoprazole: Nursing Drug Guide, Pre-meal Dosing & NCLEX Review
On the unit, the highest-stakes lansoprazole errors are giving PPI doses with meal trays instead of before eating, missing contraindicated rilpivirine combinations, and overlooking watery diarrhea that signals C. difficile during prolonged acid suppression and recent antibiotics.
Proton pump inhibitor therapy, including lansoprazole, may be associated with an increased risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients—evaluate diarrhea that does not improve. Acute tubulointerstitial nephritis can occur at any point during PPI therapy; discontinue and evaluate if renal function declines or hypersensitivity is suspected. Lansoprazole is contraindicated with rilpivirine-containing products. Delayed-release capsules and Prevacid SoluTab must be taken before meals; giving with breakfast, chewing capsules, or crushing enteric-coated granules can blunt acid suppression. Use the lowest dose and shortest duration appropriate to the indication.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Give lansoprazole before meals (not with the tray), screen for watery diarrhea during prolonged therapy, and hold immediately for rilpivirine co-therapy, acute kidney injury with suspected tubulointerstitial nephritis, or severe hypersensitivity—symptomatic GERD relief does not rule out gastric malignancy or C. difficile.
Most common brand names
Lansoprazole is a substituted benzimidazole proton pump inhibitor—distinct from omeprazole and pantoprazole on strength, formulation, and interchange rules. Verify whether the order specifies delayed-release capsules (15 mg or 30 mg) or orally disintegrating Prevacid SoluTab per current prescribing information.
The reference brands in U.S. prescribing information are Prevacid (delayed-release capsules) and Prevacid SoluTab (delayed-release orally disintegrating tablets). Many institutions stock multiple PPIs; do not substitute another “-prazole” agent without pharmacist-approved interchange.
Why we give it — Indications
Lansoprazole is a proton pump inhibitor used to suppress gastric acid secretion. Nurses administer it for acid-mediated upper GI conditions including GERD, erosive esophagitis, duodenal and gastric ulcers, and H. pylori combination regimens; symptomatic relief does not exclude gastric malignancy—follow prescriber plans for diagnostic follow-up when indicated.
| Use | Detail |
|---|---|
| Symptomatic GERD / erosive esophagitis (EE) | Symptomatic GERD: 15 mg once daily up to 8 weeks. Short-term EE: 30 mg once daily up to 8 weeks. Maintenance of healed EE: 15 mg once daily per lansoprazole delayed-release capsules prescribing information. |
| Duodenal ulcer / peptic ulcer | Active duodenal ulcer: 15 mg once daily for 4 weeks. Maintenance of healed duodenal ulcer: 15 mg once daily per labeling. |
| NSAID-associated gastric ulcer | Healing: 30 mg once daily for 8 weeks. Risk reduction: 15 mg once daily for up to 12 weeks when patients require continued NSAID therapy per labeling. |
| H. pylori eradication (combination) | Triple therapy: lansoprazole 30 mg twice daily for 10 or 14 days with amoxicillin and clarithromycin—follow each drug’s prescribing information for contraindications and dose adjustments. |
| Pathological hypersecretory states (e.g., ZES) | Starting dose 60 mg once daily (individualized); doses above 120 mg/day should be divided per labeling—specialist-led therapy with close monitoring. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Lansoprazole belongs to the substituted benzimidazole class of antisecretory drugs. It inhibits the H+/K+ ATPase (proton pump) on gastric parietal cells, blocking the final step of acid production. The effect is dose-related and suppresses both basal and stimulated acid secretion. Because the drug is formulated as delayed-release granules, it must pass through the stomach intact and activate in the acidic parietal-cell canaliculus—crushing, chewing, or giving with food can destroy the enteric coating and reduce efficacy.
Dosing overview
Adult dosing depends on indication. In severe hepatic impairment (Child-Pugh Class C), the recommended dosage is 15 mg once daily per lansoprazole delayed-release capsules prescribing information; exposure is substantially increased compared with healthy subjects. Always verify the prescriber order, indication, and formulation against current prescribing information.
Missed dose: Take the missed dose as soon as possible; if it is almost time for the next dose, skip the missed dose and take the next dose at the regular scheduled time. Do not take two doses at the same time (lansoprazole delayed-release capsules prescribing information).
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Antisecretory effect begins within 1 hour of dosing per pharmacodynamic studies cited in labeling | Symptomatic heartburn relief may lag behind acid suppression—reassess over days, not minutes |
| Peak effect | Mean Cmax at approximately 1.7 hours after oral dosing per labeling | Do not expect full healing of erosive esophagitis within the first dose; evaluate per endoscopy or prescriber plan |
| Food effect | Cmax and AUC diminished by about 50–70% if given 30 minutes after food vs fasting; no significant food effect if given before meals per labeling | Passing lansoprazole with breakfast reduces absorption—schedule before meal trays |
| Half-life | Mean plasma half-life approximately 1.5 (±1) hours in healthy subjects per labeling | Irreversible pump inhibition prolongs clinical acid suppression; C. difficile and hypomagnesemia may appear after prolonged therapy |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm indication, dose, formulation (delayed-release capsule vs SoluTab), and that administration is scheduled before meals—not with the meal tray
- Review allergy to substituted benzimidazoles or PPI excipients; screen MAR and home list for rilpivirine-containing HIV products (contraindicated) and atazanavir-containing regimens (reduced exposure per labeling)
- Perform medication reconciliation for duplicate PPI therapy, warfarin, clopidogrel, high-dose methotrexate, digoxin, diuretics, sucralfate timing, and recent antibiotics (C. difficile risk context)
Contraindications
- Known severe hypersensitivity to any component of the lansoprazole formulation per labeling
- Patients receiving rilpivirine-containing products (contraindicated with PPIs including lansoprazole per labeling)
- When used in H. pylori triple therapy, also follow contraindications in amoxicillin and clarithromycin prescribing information
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Rilpivirine (HIV) | Contraindicated—reduced antiretroviral absorption with acid suppression | Hold lansoprazole; notify prescriber and pharmacist immediately if co-ordered or discovered on home med list |
| Warfarin | Increased INR and prothrombin time reported with PPIs and warfarin concomitantly—possible abnormal bleeding per labeling | Monitor INR and prothrombin time; notify prescriber of supratherapeutic values or bleeding |
| Clopidogrel | Concomitant lansoprazole 30 mg reduced mean AUC of clopidogrel active metabolite by ~14% in a labeling study; effect on platelet inhibition was not considered clinically important | Still flag co-therapy for pharmacist review per institutional antiplatelet/PPI protocol—do not independently substitute or stop either drug |
| High-dose methotrexate | PPIs may elevate and prolong methotrexate and/or hydroxymethotrexate levels—possible toxicity per labeling | With high-dose methotrexate, temporary PPI withdrawal may be considered—coordinate with oncology pharmacy |
| Atazanavir / nelfinavir (HIV) | Decreased antiretroviral exposure with PPI acid suppression—may reduce virologic effect per labeling | Verify HIV regimen before each dose; notify prescriber and pharmacist—follow antiretroviral prescribing information |
| Sucralfate | Concomitant sucralfate reduced lansoprazole bioavailability by 17% per labeling | Give lansoprazole at least 30 minutes before sucralfate per administration instructions |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral delayed-release capsule or Prevacid SoluTab (orally disintegrating tablet); NG administration uses labeling-specific steps when the patient cannot swallow intact dosage forms.
- Take before meals; antacids may be used concomitantly per PREVACID and lansoprazole delayed-release capsules prescribing information
- Capsules: swallow whole—do not crush or chew. May open capsule and sprinkle intact granules on applesauce, ENSURE pudding, cottage cheese, yogurt, or strained pears and swallow immediately; or mix granules in a small volume of apple, orange, or tomato juice per labeling
- NG tube (capsule, ≥16 French): open capsule, mix intact granules in 40 mL apple juice only, administer, then flush with additional apple juice—other liquids are not recommended per labeling
- SoluTab: place on tongue to disintegrate (do not break, cut, or chew microgranules); oral-syringe or NG administration per labeling when swallowing is difficult
- Give lansoprazole at least 30 minutes before sucralfate per labeling
Passing lansoprazole with breakfast or crushing enteric-coated granules is a common nursing administration error: labeling notes Cmax and AUC fall by about 50–70% when the dose is given 30 minutes after food. Coordinate medication passes so PPI doses are taken before meal trays—not with the tray.
Expected therapeutic response
- Decrease in heartburn, regurgitation, or epigastric discomfort when used for symptomatic GERD
- Healing of erosive esophagitis documented by endoscopy or prescriber assessment when applicable—not assessed at the bedside alone
- Absence of new alarm symptoms (dysphagia, odynophagia, GI bleeding, unintentional weight loss) that require malignancy workup despite PPI response
Red flags — Stop and act
Stop lansoprazole and escalate when serious PPI-associated complications or contraindicated combinations are suspected. Symptomatic acid relief alone does not exclude gastric malignancy or infectious colitis.
- Watery diarrhea that does not improve—consider Clostridium difficile-associated diarrhea and antibiotic-associated diarrhea, especially during hospitalization or after antibiotics
- Decreased urine output, rising creatinine, malaise, or non-specific symptoms with suspected acute tubulointerstitial nephritis—discontinue PPI and notify prescriber per labeling
- New widespread rash, mucosal lesions, fever, or eosinophilia suggesting severe cutaneous adverse reaction (SJS/TEN/DRESS/AGEP) or lupus-like syndrome
- Abdominal pain, dysphagia, GI bleeding, anemia, or weight loss despite PPI therapy—may signal gastric malignancy requiring diagnostic evaluation
- Tetany, arrhythmias, or seizures with prolonged PPI therapy—evaluate for hypomagnesemia and mineral abnormalities per labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Headache, diarrhea, nausea, flatulence, abdominal pain, constipation, dry mouth | Most common in adults (>1%) per lansoprazole delayed-release capsules prescribing information | Document and trend; evaluate non-improving diarrhea for C. difficile |
| C. difficile-associated diarrhea | Serious; increased risk with PPI therapy in observational studies | Discontinue PPI per prescriber/infection-control protocol; obtain stool studies; initiate isolation precautions per facility policy |
| Acute tubulointerstitial nephritis | Serious; may occur at any time during therapy | Stop lansoprazole; notify prescriber; monitor creatinine and urine output |
| Hypomagnesemia | Rare with prolonged PPI use (≥3 months, often ≥1 year) | Consider magnesium monitoring with diuretics or digoxin; report tetany or arrhythmias |
| Severe cutaneous reactions (SJS, TEN, DRESS, AGEP) | Serious; potentially fatal | Discontinue at first signs; urgent dermatology/medical evaluation |
| Fractures (hip, wrist, spine) | Associated with long-term and high-dose PPI therapy in observational studies | Encourage shortest effective duration; bone health counseling in at-risk patients |
On a small screen, swipe or scroll sideways to see the full table.
Most common reactions (≥1%): diarrhea, abdominal pain, nausea, and constipation per lansoprazole delayed-release capsules prescribing information; serious warnings include C. difficile-associated diarrhea, acute tubulointerstitial nephritis, and severe cutaneous reactions.
Overdose, toxicity, and antidote
In one reported overdose, a patient consumed 600 mg of lansoprazole delayed-release capsules with no adverse reaction per overdosage labeling. Oral doses up to 5000 mg/kg in animals did not produce deaths or clinical signs. Not specified in the reviewed prescribing information whether higher human exposures produce a characteristic toxidrome.
Management
- No specific antidote for lansoprazole is known per labeling
- Treatment is symptomatic and supportive
- Lansoprazole is not removed by hemodialysis per overdosage labeling
- Monitor vital signs and mental status; supportive care as clinically indicated
Contact local poison control or medical toxicology services for over-exposure guidance per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- Lansoprazole vs omeprazole—sound-alike PPIs with different mg strengths and interchange rules; verify correct drug on MAR and pharmacy label
- Prevacid vs Prevacid SoluTab—same drug, different administration technique; SoluTab contains phenylalanine (relevant for phenylketonuria per labeling)
- Lansoprazole vs other “-prazole” agents (omeprazole, pantoprazole, rabeprazole)—different mg strengths; do not assume therapeutic interchange
- Duplicate PPI therapy—inpatient lansoprazole plus home OTC omeprazole increases adverse-effect risk without added benefit
- Crushing or chewing delayed-release products—labeling states products should not be crushed or chewed; destroys enteric coating
- Administration with meal trays—common workflow error; take before meals, not with food
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Do not crush or chew capsules or SoluTab. Open capsule only for labeled soft-food or juice administration, or apple-juice NG protocol—granules must stay intact. |
| Food timing | Take before meals; coordinate med pass before breakfast/lunch trays—not with the tray. |
| Enteral tube | Capsule granules: 40 mL apple juice only, then flush. SoluTab: disperse in syringe per labeling within 15 minutes—do not substitute other liquids for apple-juice capsule protocol. |
| Storage | Store at room temperature per product labeling. |
| Lab timing | Stop PPI at least 14 days before chromogranin A testing for neuroendocrine tumor investigations per labeling; monitor magnesium in prolonged therapy with diuretics or digoxin. |
| Commonly missed | Home OTC PPI, duplicate inpatient PPI orders, rilpivirine on HIV regimen, and giving dose with meal instead of before. |
| Ask pharmacy when | Pediatric suspension compounding, tube administration, drug interaction with clopidogrel/methotrexate, or de-escalation after healing course. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Hospitalized / antibiotic-exposed patients | Higher risk context for C. difficile-associated diarrhea with PPI therapy per observational studies in labeling—pair diarrhea surveillance with infection-prevention practices. |
| Severe hepatic impairment | Exposure substantially increased; recommended dosage 15 mg once daily in Child-Pugh Class C per labeling. Review liver function tests and alcohol use. |
| Long-term or high-dose PPI use | Increased fracture, hypomagnesemia, vitamin B-12 deficiency, and fundic gland polyp risks with prolonged therapy—reassess need for continued PPI at transitions of care. |
| Pregnancy | Published observational studies overall do not indicate an association of adverse pregnancy outcomes with lansoprazole per labeling; animal data at high exposures showed fetal bone and growth effects—advise pregnant patients of potential fetal risk and use only if clearly needed. |
| Lactation | No information on lansoprazole in human milk per labeling; lansoprazole and metabolites are present in rat milk. Balance breastfeeding benefits with maternal clinical need and potential infant exposure. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- GI symptoms—heartburn relief, nausea, abdominal pain, and stool character (watery diarrhea, blood, melena)
- Renal function and urine output when prolonged therapy or declining status—acute tubulointerstitial nephritis may present with non-specific symptoms per labeling
- Basic metabolic panel trends including creatinine; consider magnesium in patients on long-term PPIs with diuretics, digoxin, or neuromuscular symptoms
Document
- Dose, formulation, time administered relative to meals (document if given before meals—not with the meal tray)
- Indication, planned duration of therapy, and de-escalation or reassessment dates when ordered
- Patient education on timing before meals, diarrhea reporting, and not crushing delayed-release capsules
Patient teaching
- Take this medicine before meals with water; swallow capsules whole—do not crush or chew SoluTab or capsules unless using a pharmacy-approved administration method
- Report watery diarrhea, fever, blood in stool, black tarry stools, worsening abdominal pain, or swallowing difficulty promptly
- Tell your care team about all medicines—including OTC PPIs, HIV medicines, clopidogrel, methotrexate, and herbal products such as St. John’s wort
- Do not stop or double doses without prescriber advice; if a dose is missed, take when remembered unless the next dose is soon (do not take two doses at once per labeling)
- Seek urgent care for severe rash, facial swelling, trouble breathing, muscle spasms, or irregular heartbeat during long-term use
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to substituted benzimidazoles or formulation components
- Patient is receiving rilpivirine-containing products (contraindicated)
- Order is to administer with or immediately after a meal when labeling requires dosing before meals
- Watery diarrhea not improving, suspected C. difficile, acute kidney injury with possible tubulointerstitial nephritis, or severe cutaneous reaction
- Duplicate PPI therapy without prescriber intent, or crushed/chewed delayed-release capsule order without pharmacy-approved tube protocol
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
PPI passes look simple, but timing and interaction checks prevent the failures that matter on med-surg and critical-care units: C. difficile during prolonged acid suppression, missed rilpivirine contraindications, and doses given with meal trays instead of before food.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and timing before meals (not with the meal tray)
- Screen HIV regimen for rilpivirine and atazanavir; review warfarin INR needs, antiplatelet therapy, and methotrexate orders
- Confirm delayed-release capsule or SoluTab is intact—never crush or chew without pharmacy-approved administration steps
- Check for duplicate PPI therapy on MAR and home medication list
2. High-alert and safety badge
Not a traditional high-alert medication—PPI safety focusLansoprazole is not universally listed as a high-alert drug, but prolonged PPI therapy carries serious infection, renal, and interaction risks. Treat rilpivirine co-therapy and administration-timing errors with the same urgency as high-alert checks.
3. Clinical workflow: hold and question rules
- If breakfast is arriving in 15 minutes and lansoprazole was not given, hold and reschedule to preserve pre-meal timing unless prescriber documents otherwise
- If the patient develops watery diarrhea on hospital day 10 while on PPI and antibiotics, hold further doses and initiate stool C. difficile workup per protocol
- Stop and clarify if two PPIs appear active—common after admission when home omeprazole overlaps inpatient lansoprazole
4. Critical teach-back questions
- “When should you take this medicine in relation to breakfast?” (Before eating—not with the meal tray.)
- “What bowel changes should you report while on this stomach medicine?” (Watery diarrhea, especially if frequent or accompanied by fever—possible C. difficile.)
5. Care coordination
Pharmacist: Interaction checks (rilpivirine, clopidogrel, methotrexate), pediatric suspension compounding, NG administration, and PPI de-escalation after healing course
Prescriber / gastroenterology: Alarm symptoms despite therapy, need for endoscopy, H. pylori regimen changes, or prolonged PPI without documented indication
🧠 Quick mental checklist
- Was this dose scheduled before the next meal—not with the tray?
- Is the patient on rilpivirine or another contraindicated interacting drug?
- Any watery diarrhea, recent antibiotics, or hospital day >7 on PPI?
- Are two PPIs active on the MAR or home list?
- Is there a planned stop date—or has therapy continued without reassessment?
Lansoprazole NCLEX practice questions
Practice NCLEX-style clinical judgment practice for lansoprazole with a tabbed med-surg case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), electrolyte trend interpretation, matrix urgency sorting, interaction judgment, and administration cloze—recognise cues → analyse → prioritise → act → evaluate outcomes when diarrhea persists despite PPI therapy.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Lansoprazole 30 mg PO daily — scheduled 0730 (before breakfast); documented given 0745 with breakfast tray
- IV antibiotic (day 9 of course) — given 0800 per MAR
- Home medication list shows omeprazole 20 mg daily—continued on admission without stop date
- 0900: new order to add rilpivirine-containing HIV regimen—pharmacy verification pending
- Admission BMP: creatinine 0.9 mg/dL, magnesium 1.9 mg/dL
- Today (hospital day 12): creatinine 1.3 mg/dL (↑ from 1.0 yesterday); magnesium 1.3 mg/dL (low)
- WBC 13.2 ×109/L; stool C. difficile PCR ordered—result pending
- 62-year-old with pneumonia complicated by GERD flare; hospital day 12
- Completed 7 days of broad-spectrum antibiotic therapy; now on narrower-spectrum IV antibiotic
- On lansoprazole since admission for stress-ulcer prophylaxis—no documented reassessment
- HIV-positive on new antiretroviral regimen (includes rilpivirine) starting today per infectious disease
- 0730: Breakfast tray arrived early; lansoprazole given with applesauce and coffee
- 1000–1200: Three loose watery stools; mild cramping; abdomen soft, non-distended
- 1215: Patient asks nurse to “keep the stomach pill with meals so it works better”
Answer key & rationale
Frequently asked questions
When should lansoprazole be taken in relation to meals?
Lansoprazole delayed-release capsules and Prevacid SoluTab prescribing information instruct patients to take doses before meals. Nurses should coordinate medication passes so PPI doses are not given with meal trays.
When should a nurse hold lansoprazole?
Hold for hypersensitivity to substituted benzimidazoles, rilpivirine-containing products (contraindicated), suspected acute tubulointerstitial nephritis, severe cutaneous reaction, watery diarrhea not improving (possible C. difficile), orders to give with meals when labeling requires pre-meal dosing, or duplicate PPI therapy without prescriber intent.
Does lansoprazole increase Clostridium difficile risk?
Observational studies cited in lansoprazole delayed-release capsules prescribing information suggest PPI therapy may be associated with increased C. difficile-associated diarrhea, especially in hospitalized patients. Consider this diagnosis when diarrhea does not improve and use the shortest effective PPI duration.
Is there an antidote for lansoprazole overdose?
No specific antidote is known per overdosage labeling. Treatment is symptomatic and supportive; lansoprazole is not removed by hemodialysis. Contact local poison control or toxicology services per facility protocol for over-exposure.
Can lansoprazole be used during pregnancy or breastfeeding?
Observational studies overall do not indicate an association of adverse pregnancy outcomes with lansoprazole per labeling; animal data at high exposures showed fetal effects—advise pregnant patients of potential fetal risk. For lactation, there is no information on lansoprazole in human milk; balance breastfeeding benefits with maternal clinical need.
Why must lansoprazole be held with rilpivirine?
PPIs are contraindicated with rilpivirine-containing products because gastric acid suppression reduces rilpivirine absorption and virologic efficacy. Verify HIV medications on every admission and before each dose.
References
-
U.S. National Library of Medicine. LANSOPRAZOLE delayed-release capsules — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee80a19-e514-41e6-9153-c959699d97b1
-
U.S. National Library of Medicine. PREVACID (lansoprazole) delayed-release capsules and PREVACID SoluTab — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7140f8d9-e478-4f69-a4eb-3fd4c9414576
-
World Health Organization. Helicobacter pylori infection — Fact sheet.https://www.who.int/news-room/fact-sheets/detail/helicobacter-pylori-infection
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump
-
U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump
-
National Institute for Health and Care Excellence (NICE). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184).https://www.nice.org.uk/guidance/cg184
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.